
|Videos|July 31, 2020
ASRS 2020: AsclepiX lead candidate holds potential for wet AMD, DME, RVO
Author(s)Alex Delaney-Gesing
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.
Advertisement
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis, during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Timely interventions can protect vision in patients with GA
2
Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
3
FLORetina 2025: Long-term follow-up in pediatric gene therapy
4
Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal Vascular Diseases
5










































